Bhubaneswar: A Government expert panel on Wednesday recommended granting regular market approval to Covishield and Covaxin, subject to certain conditions.
The vaccines against COVID-19, manufactured by both Serum Institute of India (SII) and Bharat Biotech was authorised for emergency use in the country.
The two vaccines were granted Emergency Use Authorisation (EUA) on 3 January. The recommendations will be sent to DCGI for final approval.
Pharma companies Serum Institute of India (SII) and Bharat Biotech had submitted applications to the Drugs Controller General of India (DCGI) seeking regular market authorisation for their respective vaccines.
Both Covaxin and Covishield are currently authorized for emergency use only. Market authorisation label for a vaccine means it can be authorised for use without reservations or conditions.
